Please try another search
Cyfuse Biomedical K.K. engages in the development, manufacture, and sale of regenerative medicine products in Japan. It develops cellular products in the field of regenerative therapy; and undertakes contract for cellular products for research and development. The company also offers Bio 3D Printer for use in the regeneration of various tissues and organs, such as cartilage and bones, blood vessels, and nerves; regenova, a bio 3D printer for 3D stacking of cells; and S-PIKE that develops 3D-structures from cells. Cyfuse Biomedical K.K. was incorporated in 2010 and is based in Tokyo, Japan.
Name | Age | Since | Title |
---|---|---|---|
Shizuka Akieda | - | - | CEO & Director |
Masahiro Sanjo | - | - | CFO, Head of Corporate Planning & Business Administration and Director |
Takuo Hirose | 53 | 2021 | Audit & Supervisory Board Member |
Yoichi Oda | 46 | 2018 | Audit & Supervisory Board Member |
Kunihiko Suzuki | 65 | 2021 | Independent Outside Director |
Yasuhiro Yoshioka | 69 | 2019 | Independent Outside Director |
Kazuya Oda | 63 | 2021 | Audit & Supervisory Board Member |
Norihiko Tokunaga | 48 | 2021 | GM of System Development Department & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review